Centre of Excellence for Health, Immunity, and Infections (CHIP), Copenhagen University Hospital/Rigshospitalet, Copenhagen, Denmark.
Department of Hematology, Copenhagen University Hospital/Rigshospitalet, Copenhagen, Denmark.
Eur J Haematol. 2024 May;112(5):802-809. doi: 10.1111/ejh.14172. Epub 2024 Jan 6.
Improved survival after hematopoietic cell transplantation (HCT) and an increasingly comorbid transplant population may give rise to new trends in the causes of death.
This study includes all adult allogeneic HCT recipients transplanted at Rigshospitalet between January 1, 2010 and December 31, 2019. Underlying causes of death were determined using the Classification of Death Causes after Transplantation (CLASS) method.
Among 802 HCT recipients, 289 died during the study period. The main causes of death were relapse (N = 133, 46.0%), graft-versus-host disease (GvHD) (N = 64, 22.1%) and infections (N = 35, 12.1%). Multivariable analyses showed that with increasing transplant calendar year, a decreased risk of all-cause mortality (HR 0.92, 95% CI 0.87-0.97) and death from GvHD (HR 0.87, 95% CI 0.78-0.97) was identified, but not for other specific causes. Standardized mortality ratios (SMRs) for all-cause mortality decreased from 23.8 (95% CI 19.1-28.5) to 18.4 (95% CI 15.0-21.9) for patients transplanted in 2010-2014 versus 2015-2019, while SMR for patients who died from GvHD decreased from 8.19 (95% CI 5.43-10.94) to 3.65 (95% CI 2.13-5.18).
As risk of all-cause mortality and death from GvHD decreases, death from relapse remains the greatest obstacle in further improvement of survival after HCT.
造血细胞移植(HCT)后生存率的提高和移植人群中合并症的增加可能会导致死亡原因出现新趋势。
本研究纳入了 2010 年 1 月 1 日至 2019 年 12 月 31 日在 Rigshospitalet 接受异基因 HCT 的所有成年患者。采用移植后死亡原因分类(CLASS)方法确定死亡的根本原因。
在 802 例 HCT 受者中,289 例在研究期间死亡。主要死亡原因是复发(N=133,46.0%)、移植物抗宿主病(GvHD)(N=64,22.1%)和感染(N=35,12.1%)。多变量分析显示,随着移植时间的推移,全因死亡率(HR 0.92,95%CI 0.87-0.97)和 GvHD 死亡率(HR 0.87,95%CI 0.78-0.97)的风险降低,但其他特定原因的死亡率没有降低。全因死亡率的标准化死亡率比(SMR)从 2010-2014 年移植患者的 23.8(95%CI 19.1-28.5)降至 2015-2019 年移植患者的 18.4(95%CI 15.0-21.9),而 GvHD 死亡患者的 SMR 从 8.19(95%CI 5.43-10.94)降至 3.65(95%CI 2.13-5.18)。
随着全因死亡率和 GvHD 死亡率的降低,复发导致的死亡仍然是 HCT 后生存率进一步提高的最大障碍。